This is an index of side effect / adverse reaction reports (a.k.a. adverse event reports) related to Mesna and submitted to the FDA during the sample period of about a year. The information is not vetted and should not be considered as verified clinical evidence.
Reports by Event Outcome
All Cases (163)
Death (29)
Life Threatening Events (23)
Reports by Reaction Type
Febrile Neutropenia (34),
Mucosal Inflammation (23),
Epistaxis (21),
Candida Test Positive (18),
Hypotension (17),
Off Label Use (15),
Fatigue (14),
Infection (13),
Pyrexia (13),
Pneumonia (11),
Encephalopathy (11),
Hepatotoxicity (9)
Below are a few examples of reports where side effects / adverse reactions may be related to Mesna. For a complete list or a specific selection of reports, please use the links above.
Possible Mesna side effects in 59 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-23
Patient: 59 year old female
Reactions: Encephalopathy
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Carboplatin
Start date: 2012-07-20
End date: 2012-07-20
Etoposide
Start date: 2012-07-19
End date: 2012-07-21
Mesna
Start date: 2012-07-20
End date: 2012-07-21
Mabthera
Start date: 2012-07-19
End date: 2012-07-19
Ifosfamide
Start date: 2012-07-20
End date: 2012-07-21
Other drugs received by patient: Solu-Medrol; Acetaminophen; Polaramine
Possible Mesna side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-16
Patient: female, weighing 87.8 kg (193.2 pounds)
Reactions: Neuropathy Peripheral, Upper Respiratory Tract Infection, Urinary Tract Infection, Pleural Effusion, Pyrexia, Leukocytosis, Sinusitis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 40 mg, unk
Administration route: Oral
Indication: Mantle Cell Lymphoma
Cytarabine
Dosage: 1.87 g, cyclic
Indication: Mantle Cell Lymphoma
Velcade
Dosage: 0.7 mg/m2, cyclic
Start date: 2012-03-19
Vincristine
Dosage: 2 mg, cyclic
Indication: Mantle Cell Lymphoma
Velcade
Dosage: 2.77 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-12-31
Velcade
Dosage: 0.7 mg/m2, cyclic
Velcade
Dosage: 0.7 mg/m2, cyclic
Start date: 2012-02-26
Rituximab
Dosage: 1 mg/m2, cyclic
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 50 mg/m2, unk
Indication: Mantle Cell Lymphoma
Methotrexate
Indication: Mantle Cell Lymphoma
Mesna
Dosage: 600 mg/m2, unk
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sennosides A+B; Nystatin; Diphenhydramine Hydrochloride; Neupogen; Fluconazole; Zofran; Valtrex; Sodium Chloride; Meperidine HCL; Potassium Chloride; Leucovorin Calcium; Zofran; Sodium Chloride; Sodium Chloride; Sodium Chloride; Heparin; Leucovorin Calcium; Allopurinol; Lovenox; Morphine; Senokot; Cipro / 00042702 /; Lovenox; Prednisolone Acetate; Stomatologicals, Mouth Preparations; Tramadol; Sodium Bicarbonate
Possible Mesna side effects in 41 year old male
Reported by a physician from NEW Zealand on 2012-08-13
Patient: 41 year old male
Reactions: Pancytopenia, Normochromic Normocytic Anaemia, Photodermatosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Indication: Cystitis Haemorrhagic
Cyclophosphamide
Dosage: 150mg daily
Indication: Wegener's Granulomatosis
Other drugs received by patient: Prednisone TAB; Calcium
Possible Mesna side effects in 41 year old male
Reported by a health professional (non-physician/pharmacist) from NEW Zealand on 2012-08-13
Patient: 41 year old male
Reactions: Photodermatosis
Drug(s) suspected as cause:
Mesna
Possible Mesna side effects in female
Reported by a physician from Israel on 2012-08-08
Patient: female, weighing 73.5 kg (161.7 pounds)
Reactions: General Physical Health Deterioration
Adverse event resulted in: death
Drug(s) suspected as cause:
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-17
Etoposide
Dosage: 90mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Ifosfamide
Dosage: 1200mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Dexamethasone
Dosage: 40mg every 3 weeks
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-18
Cytarabine
Dosage: 4mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-19
Cisplatin
Dosage: 100mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-18
Methotrexate
Dosage: 30mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Mesna
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Possible Mesna side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-07
Patient: female
Reactions: Encephalopathy
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Start date: 2012-04-05
End date: 2012-04-06
Mesna
Start date: 2012-03-15
Mesna
Indication: Breast Cancer
Start date: 2012-02-23
Mesna
Start date: 2012-04-05
Ifosfamide
Indication: Breast Cancer
Start date: 2012-02-23
Ifosfamide
Start date: 2012-03-15
Possible Mesna side effects in female
Reported by a physician from Israel on 2012-08-06
Patient: female, weighing 73.5 kg (161.7 pounds)
Reactions: Encephalopathy
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Cisplatin
Dosage: 100mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-18
End date: 2012-06-18
Methotrexate
Dosage: 30mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Dexamethasone
Dosage: 40mg every 3 weeks
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-18
End date: 2012-06-21
Cytarabine
Dosage: 4gm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-19
Etoposide
Dosage: 90mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Ifosfamide
Dosage: 1200mgm2 every 3 weeks
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-07-17
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma Recurrent
Start date: 2012-06-17
Possible Mesna side effects in 51 year old female
Reported by a physician from United States on 2012-08-02
Patient: 51 year old female
Reactions: Subdural Haematoma, Pleural Effusion, Purpura, Hydropneumothorax
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Methylprednisolone
Dosage: 300 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-14
Vincristine Sulfate
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-04-15
Filgrastim
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-04-24
Cytarabine
Dosage: 16540 mg, total
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-15
Leucovorin Calcium
Dosage: 140 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-14
Doxorubicin HCL
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-04-08
Dexamethasone
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-04-17
Sprycel
Dosage: 700 mg, total
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-21
Cyclophosphamide
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-04-08
Methotrexate Sodium
Dosage: 1382 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-11
Mesna
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Possible Mesna side effects in female
Reported by a physician from United States on 2012-08-01
Patient: female, weighing 87.8 kg (193.2 pounds)
Reactions: Neuropathy Peripheral, Upper Respiratory Tract Infection, Urinary Tract Infection, Pleural Effusion, Sinusitis, Leukocytosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Velcade
Indication: Mantle Cell Lymphoma
Start date: 2012-02-26
Mesna
Dosage: 1122mg in normal saline 2000 ml over 24 hours daily for 3 days on days 2-4
Indication: Mantle Cell Lymphoma
Cytarabine
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 94 mg over 15 minutes for 1 dose on day 5
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Indication: Mantle Cell Lymphoma
Velcade
Velcade
Dosage: push over 3-5 seconds
Start date: 2012-03-19
End date: 2012-03-19
Methotrexate
Indication: Mantle Cell Lymphoma
Rituximab
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: on days 2-5 and days 12-15
Administration route: Oral
Indication: Mantle Cell Lymphoma
Velcade
Start date: 2011-12-31
Vincristine
Dosage: on day 5 and day 12
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sodium Chloride; Tramadol HCL; Leucovorin Calcium; Leucovorin Calcium; Unknown Medication; Morphine Sulfate; Sodium Chloride; Neupogen; Zofran; Sennosides-Docusate Sodium; Ondansetron HCL; Potassium Chloride; Sodium Chloride; Heparin; Zofran; Sodium Bicarbonate; Meperidine HCL; Diphenhydramine HCL; Nystatin; Lovenox; Sodium Chloride; Senokot; Allopurinol; Ciprofloxacin HCL; Fluconazole; Lovenox; Prednisolone Acetate; Stomatologicals, Mouth Preparations; Valtrex; Ondansetron HCL
Possible Mesna side effects in 24 year old female
Reported by a consumer/non-health professional from United States on 2012-07-30
Patient: 24 year old female, weighing 51.0 kg (112.2 pounds)
Reactions: Abdominal Pain, Hyperkalaemia, Disseminated Intravascular Coagulation, Gastrointestinal Necrosis, Acidosis, Nephrolithiasis, Skin Discolouration, Ecchymosis, Clostridial Infection, Emphysema, White Blood Cell Count Decreased, Hypotension, Anaemia, Condition Aggravated, Soft Tissue Infection, Sepsis, Flank Pain, Colitis, Cardiac Arrest, Sinus Tachycardia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Sprycel
Dosage: last dose on 26jun12
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Cytarabine
Dosage: last dose:17jun12 route:intra ommya
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Vincristine Sulfate
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Filgrastim
Dosage: last dose:18jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
End date: 2012-01-01
Leucovorin Calcium
Dosage: last dose :21may12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Methotrexate
Dosage: last dose:13jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Dexamethasone
Dosage: last dose:16jun12
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Doxorubicin HCL
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Mesna
Dosage: last dose:17jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Cyclophosphamide
Dosage: last dose on 16jun12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Methylprednisolone
Dosage: last dose:21may12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-05-17
Possible Mesna side effects in male
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-27
Patient: male
Reactions: Angioedema, Dystonia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Primperan TAB
Dosage: 2 vials
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Vincristine
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Mesna
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Ifosfamide
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Etoposide
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Other drugs received by patient: Polyethylene Glycol; Oxycodone HCL; Paroxetine HCL; Acetaminophen; Lovenox; Esomeprazole; Xanax
Possible Mesna side effects in male
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-25
Patient: male
Reactions: Angioedema, Dystonia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Primperan TAB
Dosage: 2 vials
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Etoposide
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Vincristine
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Start date: 2012-06-25
Ifosfamide
Indication: Ewing's Sarcoma
Start date: 2012-06-25
End date: 2012-06-27
Other drugs received by patient: Acetaminophen; Xanax; Polyethylene Glycol; Paroxetine HCL; Oxycodone HCL; Esomeprazole; Lovenox
Possible Mesna side effects in 51 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-20
Patient: 51 year old female, weighing 39.0 kg (85.8 pounds)
Reactions: Subdural Haematoma, Pleural Effusion, Purpura, Hydropneumothorax
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: last dose on 7apr2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Cytarabine
Dosage: last dose on 15may2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Vincristine Sulfate
Dosage: last dose :15apr2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Cyclophosphamide
Dosage: last dose on 8apr2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Sprycel
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-21
Methotrexate
Dosage: last dose on 11may2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Doxorubicin HCL
Dosage: last dose on 08apr12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Methylprednisolone
Dosage: last dose on 14may12
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
End date: 2012-05-14
Dexamethasone
Dosage: last dose on 17apr2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Filgrastim
Dosage: last dose on 24apr2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Leucovorin Calcium
Dosage: last dose:14may2012
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-05
Possible Mesna side effects in male
Reported by a consumer/non-health professional from South Africa on 2012-07-20
Patient: male
Reactions: Haematuria
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Indication: Synovial Sarcoma
Holoxan Vial 2G
Indication: Synovial Sarcoma
Adriamycin PFS
Indication: Chemotherapy
Possible Mesna side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-07-20
Patient: 46 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Neutropenia, Thrombocytopenia, Leukopenia
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Ifosfamide
Start date: 2012-05-17
End date: 2012-05-18
Mesna
Start date: 2012-05-17
End date: 2012-05-18
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-18
Patient: female, weighing 13.1 kg (28.8 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Fluconazole; Levomepromazine; Cotrim; Docusate; Ondansetron; Gentamicin; Morphine; Moviprep; Neupogen; Neupogen; Dihydrocodeine Bitartrate INJ; Acetaminophen; Ondansetron; Docusate; Docusate; Piperacillin and Tazobactam; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron
Possible Mesna side effects in female
Reported by a physician from United States on 2012-07-17
Patient: female, weighing 12.4 kg (27.3 pounds)
Reactions: Dyspnoea, Unresponsive To Stimuli, Anaphylactic Reaction, Mental Status Changes, Acute Respiratory Distress Syndrome, Pleural Effusion, Apnoea, Cough, Oxygen Saturation Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 36 mg
Doxorubicin Hydrochloride
Dosage: 27 mg
Vincristine Sulfate
Dosage: .9 mg
Mesna
Dosage: 145 mg
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-13
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine and Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Ondansetron; Ondansetron; Gentamicin; Moviprep; Moviprep; Levomepromazine; Moviprep; Docusate; Cotrim; Docusate; Neupogen; Acetaminophen; Levomepromazine; Neupogen; Ondansetron; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Docusate; Morphine; Emollient Cream (Unk Ingredients)
Possible Mesna side effects in 46 year old male
Reported by a physician from United States on 2012-07-12
Patient: 46 year old male
Reactions: Febrile Neutropenia, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituxan
Dosage: 698 mg, unk
Start date: 2012-05-02
Mesna
Dosage: 1116 mg, unk
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 446 mg, unk
Doxorubicin HCL
Dosage: 56.5 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Pegfilgrastim
Dosage: 6 mg, unk
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 630 mg, q12h
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Vincristine Sulfate
Dosage: 2 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
Doxorubicin HCL
Dosage: 37 mg, unk
Dexamethasone
Dosage: 40 mg, unk
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
Rituxan
Dosage: 787.5 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Other drugs received by patient: MS Contin; Valtrex; Omeprazole; Ciprofloxacin; Morphine Sulfate; Enoxaparin / 01708202 /; Compazine; Fluconazole; Metoprolol Tartrate
Possible Mesna side effects in 46 year old male
Reported by a physician from United States on 2012-07-09
Patient: 46 year old male
Reactions: Febrile Neutropenia, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Neulasta
Doxorubicin HCL
Vincristine
Neulasta
Indication: non-Hodgkin's Lymphoma
Mabthera
Start date: 2012-05-02
Mabthera
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Vincristine
Indication: non-Hodgkin's Lymphoma
Mesna
Cyclophosphamide
Dexamethasone
Administration route: Oral
Mesna
Indication: non-Hodgkin's Lymphoma
Dexamethasone
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Valtrex; Omeprazole; Fluconazole; Metoprolol; Morphine; Ciprofloxacin; MS Contin; Enoxaparin; Compazine
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-06
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Levomepromazine; Docusate; Piperacillin and Tazobactam; Cotrim; Gentamicin; Ondansetron; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron; Docusate; Moviprep; Neupogen; Acetaminophen; Levomepromazine; Moviprep; Docusate
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-02
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Vinorelbine Tartrate
Dosage: last dose prior to sae 08/may/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Cyclophosphamide
Dosage: last dose prior to sae 06/06/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Avastin
Dosage: frequency: day 1, last dose prior to sae: 21/05/2012
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Moviprep; Cotrim; Morphine; Docusate; Docusate; Gentamicin; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Piperacillin and Tazobactam; Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Docusate; Neupogen
Possible Mesna side effects in male
Reported by a pharmacist from United States on 2012-06-29
Patient: male, weighing 21.3 kg (46.9 pounds)
Reactions: B-Cell Lymphoma, Hypotension, Alanine Aminotransferase Increased, Pancytopenia, Roseolovirus Test Positive, Aspartate Aminotransferase Increased, Venoocclusive Liver Disease, Acute Respiratory Distress Syndrome, Renal Failure Acute
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Fludarabine Phosphate
Indication: Product Used FOR Unknown Indication
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B-Cell Lymphoma
Start date: 2011-12-27
End date: 2012-01-16
Mesna
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Possible Mesna side effects in male
Reported by a physician from Poland on 2012-06-22
Patient: male, weighing 58.0 kg (127.6 pounds)
Reactions: Pneumonia, Circulatory Collapse, Altered State of Consciousness
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Etoposide
Dosage: 96mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Mesna
Dosage: 128mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Cytosar-U
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-17
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
Ifosfamide
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Other drugs received by patient: Zokzid; Metronidazole; Albuminar-20; Sodium Chloride 0.9%; Diflucan; Meropenem; 5% Glucose; Furosemide
Possible Mesna side effects in male
Reported by a physician from Poland on 2012-06-19
Patient: male, weighing 58.0 kg (127.6 pounds)
Reactions: Pneumonia, Circulatory Collapse, Altered State of Consciousness
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Etoposide
Dosage: 96mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Cytosar-U
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-17
Ifosfamide
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Mesna
Dosage: 128mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
Other drugs received by patient: Furosemide; Albuminar-20; Zokzid; Diflucan; 5% Glucose; Meropenem; Metronidazole; Sodium Chloride 0.9%
Possible Mesna side effects in male
Reported by a physician from Poland on 2012-06-15
Patient: male, weighing 58.0 kg (127.6 pounds)
Reactions: Pneumonia, Blood PH Decreased, Haemoglobin Decreased, Haematocrit Decreased, Gamma-Glutamyltransferase Increased, RED Blood Cell Count Decreased, Circulatory Collapse, Platelet Count Decreased, Altered State of Consciousness
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Etoposide
Dosage: 96mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Cytosar-U
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-17
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
Mesna
Dosage: 128mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Ifosfamide
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Other drugs received by patient: Diflucan; Albuminar-20; Metronidazole; Zokzid; Meropenem; 5% Glucose; Furosemide; Sodium Chloride 0.9%
Possible Mesna side effects in male
Reported by a physician from Poland on 2012-06-14
Patient: male, weighing 58.0 kg (127.6 pounds)
Reactions: Pneumonia, Circulatory Collapse, Altered State of Consciousness
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Etoposide
Dosage: 96mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Mesna
Dosage: 128mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-20
Ofatumumab
Dosage: 1000mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
Cytosar-U
Dosage: 1600mg cyclic
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2012-05-16
End date: 2012-05-17
Other drugs received by patient: Metronidazole; Meropenem; Furosemide; Zokzid; Diflucan; Sodium Chloride 0.9%; Albuminar-20; 5% Glucose
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-12
Patient:
Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Condition Aggravated, Febrile Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Prophylaxis
Methylprednisolone
Indication: Prophylaxis
Rituximab
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Prophylaxis
Mesna
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Mesna
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Other drugs received by patient: Blood Products; Acyclovir; Antibiotics; Neupogen
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-08
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Prophylaxis
Prednisone
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Mesna
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Prophylaxis
Mesna
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Methotrexate
Indication: Prophylaxis
Other drugs received by patient: Neupogen; Acyclovir; Antibiotics; Blood Products
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-08
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Methylprednisolone
Indication: Prophylaxis
Mesna
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Cytarabine
Indication: Prophylaxis
Rituximab
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Prophylaxis
Mesna
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Prednisone
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Other drugs received by patient: Neupogen; Blood Products; Acyclovir; Antibiotics
|